Trial reportThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2013
Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET).
Trial report in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.The Lancet. Neurology · 2025Trial
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.International psychogeriatrics · 2024Trial
- Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial.International psychogeriatrics · 2014Trial
- Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.The Journal of clinical psychiatry · 2013Trial
- Loss of neuronal population organization links pathology to behavior in a model of Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Targeting central immune signaling enhances the effects of methylphenidate in alleviating apathy-like behavior in 5xFAD mice.Scientific reports · 2026Article
- Loss of neuronal population organization links pathology to behavior in a model of Alzheimer's disease.bioRxiv : the preprint server for biology · 2026Article
- Targeting central immune signaling enhances the effects of methylphenidate in alleviating apathy-like behavior in 5xFAD mice.Research square · 2025Article
- Efficacy of Methylphenidate in Patients With Brain Disease: A Systematic Review and Meta-Analysis.Brain & NeuroRehabilitation · 2025Article
- Investigating the Prevalence and Predictors of Apathy among the Canadian Long-Term Care Residents: A Secondary Data Analysis.The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres · 2024Article
- Methylphenidate for the Treatment of Post-COVID Cognitive Dysfunction (Brain Fog).Journal of medical cases · 2024Article
- Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial.JMIR research protocols · 2018Article
- The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.Trials · 2018Article
- Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?European archives of psychiatry and clinical neuroscience · 2015Review
- Principles and management of neuropsychiatric symptoms in Alzheimer's dementia.Alzheimer's research & therapy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundResearch on efficacious treatments for apathy in Alzheimer disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes.
methodsIn designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer disease, we encountered the following issues: defining and measuring apathy, distinguishing apathy and depression, determining an appropriate test treatment, selecting relevant secondary outcomes, recruiting participants, and deciding on a suitable method for treatment unmasking. ADMET is a 6-week randomized, double-masked, placebo-controlled multicenter clinical trial with two parallel treatment groups assigned in a 1:1 ratio with randomization stratified by clinical center. The recruitment goal is 60 randomized participants over 2 years. The primary outcomes are change in apathy severity as measured by the Apathy Evaluation Scale and the Alzheimer Disease Cooperative Study-Clinical Global Impression of Change.
conclusionThe design decisions made for ADMET are important elements to be considered in trials assessing the safety and efficacy of medications for clinically significant apathy in Alzheimer disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.